We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04167618
Recruitment Status : Terminated (Business priorities)
First Posted : November 19, 2019
Last Update Posted : August 18, 2022
Information provided by (Responsible Party):
Y-mAbs Therapeutics

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : August 11, 2022
Actual Study Completion Date : August 11, 2022